Alfasigma will acquire Nordic Group, adding Nordimet, €190 million in revenue and broader specialty-care operations across Europe, Canada and Japan.
Belenos says BEL512 met all Phase 2 CRSwNP endpoints, but undisclosed effect sizes make the planned 2027 Phase 3 trial the critical test.
AgelessRx wins $1 million from XPRIZE Healthspan to expand its multi-therapy longevity approach into a larger one-year clinical trial.
Silence Therapeutics raises $175 million after positive divesiran Phase 2 data, strengthening funding ahead of a planned Phase 3 PV trial.
AN2 Therapeutics is advancing three Phase 2 programs as epetraborole moves into PV and AN2-502998 approaches a Chagas proof-of-concept test.
Innoviva’s XACDURO, ZEVTERA and NUZOLVENCE reach the 2026 Prix Galien finals, spotlighting a growing anti-infective portfolio.
Theriva designs a Phase 2/3 VCN-01 retinoblastoma trial after early eye-preservation signals. See what the planned FDA meeting could change.
LB-102 Phase 3 schizophrenia data are now due in H1 2027 as faster enrollment and $150m financing accelerate LB Pharmaceuticals’ pipeline.
Sutacimig gets an FDA-backed Phase 3 path after sustained bleed reductions in Glanzmann thrombasthenia. Read what the pivotal trial must prove.
SEP-479 shows a 3-to-4-day half-life in Phase 1, supporting once-daily oral dosing. See what Septerna must prove next in hypoparathyroidism.